Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly CEO David Ricks on Monday said the company's powerful weight-loss drug Zepbound hit 25,000 new prescriptions per week at the end of December and that its 2024...
Eli Lilly CEO David Ricks on Monday said the company's powerful weight-loss drug Zepbound hit 25,000 new prescriptions per week at the end of December, and that its 2024 supply may not be enough to meet demand. "I think it's important to set expectations, but we're working hard to fulfill demand," he told Reuters at the annual JPMorgan health conference in San Francisco. Ricks declined to provide details on how much Zepbound Lilly can produce now, or to forecast 2024 demand and eventual supply.
CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will recommend biosimilar versions of the medicine instead. CVS said Hyrimoz and an unbranded version of Humira, both from Swiss drugmaker Sandoz, will be covered across all its formularies, while branded and unbranded near copies of the drug from India's Biocon will be covered on some reimbursement lists. CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produc...
Drugmakers including Pfizer, Sanofi and Takeda Pharmaceutical plan to raise prices on more than 500 drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.
Drugmakers including Pfizer, Sanofi and Takeda Pharmaceutical plan to raise prices in the United States on more than 500 drugs in early January, according to data analyzed...